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They can be founder events and are
associated with a preleukemic state.
Further studies of the mechanisms and
functions of DDX41 and other members
of the RNA helicases family in hemato-
poiesis and leukemogenesis are war-
ranted and may ultimately lead to ap-
proaches of therapeutic targeting of
these proteins.
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Emerging evidence is contributing to explain how leukemias disrupt normal blood cell production. In this
issue of Cancer Cell, Welner and colleagues show that, during the development of chronic myeloid leukemia,
mutated cells transform normal hematopoietic progenitors into ‘‘leukemic like’’ cells through IL-6 secretion,
proposing a new cellular target.Classical cancer therapies target the ma-
lignant cells. However, the environment
surrounding the tumors, referred to as
‘‘niche,’’ during cancer development and
progression is gaining increased atten-
tion. Many efforts are now directed to-
ward understanding the relationships
between the tumor and its supporting
cells (e.g., stromal cells), which have
become a novel target for therapies.
This also applies to blood proliferative
disorders, such as myeloproliferative
neoplasms (MPNs), in which the interac-
tions between tumoral and stromal cells
are critical for disease progression both
at the hematopoietic stem cell (HSC) and
progenitor level (Arranz et al., 2014;
Krause et al., 2013; Schepers et al.,
2013). However, leukemic stem cell
niches might be different in chronic and
acute myeloid leukemias. The Scaddengroup has demonstrated that activation
of osteoblastic cells by parathyroid
hormone attenuates chronic myeloge-
nous leukemia (CML), but enhances
instead MLL-AF9 oncogene-induced
acute myeloid leukemia (Krause et al.,
2013).
Using a JAK2V617F murine model, we
have recently shown that nestin+ mesen-
chymal stem cells (MSCs) play a pivotal
role in regulating the proliferation of
mutant MPN HSCs. IL-1b secreted by
mutant HSCs induces neural damage to
the niche, leading to a marked reduction
in nestin+ MSCs, uncontrolled mutant
HSC proliferation, and subsequent dis-
ease progression (Arranz et al., 2014).
Bone marrow stromal cells have been
proposed to secrete factors that protect
JAK2V617F cells from JAK2 inhibitors
(Manshouri et al., 2011). Additionally, thePassegue´ group has recently demon-
strated that CML cells induce expansion
of osteoblastic precursors that poorly
support normal hematopoietic progeni-
tors (Schepers et al., 2013).
CML is an MPN that originates in a
mutated hematopoietic stem/progenitor
cell (HSPC) carrying the t(9;22)(q34;q11)
translocation. This mutation leads to
the expression of the BCR/ABL fusion
protein, a constitutively active tyrosine
kinase that promotes the growth of
mutated HSCs and their progeny. In hu-
mans, CML presents first with a chronic
phase in which differentiated myeloid
cells accumulate. This is followed by a
short accelerated phase that precedes a
rapid blast phase when symptoms aggra-
vate as myeloid cells fail to mature and
fully differentiate (Savona and Talpaz,
2008).l 27, May 11, 2015 ª2015 Elsevier Inc. 611
Figure 1. Model of Manifestation and Progression of Myeloproliferative Neoplasms
(1) Myeloproliferative neoplasm (MPN) is originated by amutated hematopoietic stem cell (Leuk HSC) with
increased survival and proliferative capacity. Mutated HSCs secrete IL-1b, which causes damage on sym-
pathetic nervous system (SNS) nerve terminals and MSC apoptosis.
(2) Deficiently controlled by the niche, Leuk HSCs generate more mutated leukemic progenitors (Leuk
prog) and myeloid cells.
(3) Leukemic cells produce IL-6, which transforms normal leukemia-exposed progenitor cells into
‘‘leukemic-like’’ cells, boosting the proliferation of myeloid cells at the expense of lymphocytes.
(4) Both Leuk prog and leukemia-exposed progenitors secrete inflammatory cytokines that stimulate dis-
ease progression. Osteoblastic cells (OBs) proliferate and become less supportive for normal hematopoi-
etic progenitors.
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accumulation of leukemic cells in the
bone marrow impairs normal hemato-
poiesis. HSPCs progressively leave the
bone marrow and infiltrate the spleen. If
not successfully managed, the reduced
number of fully mature, functional blood
and immune cells can cause anemias,
bleedings, or infections. The displacement
of normal hematopoiesis was previously
thought tobe thepassive result of the rapid
expansion of leukemic cells in the bone
marrow cavity (Savona and Talpaz, 2008).
However, the idea of mere movement of
normal cells due to outgrowth of leukemic
cells is not supported by extramedullary
hematopoiesis occurring also with low tu-
mor burden. Alternatively, leukemic cells
can modify their niches and outcompete
normal HSPCs (Arranz et al., 2014; Col-
mone et al., 2008; Krause et al., 2013;
Schepers et al., 2013; Zhang et al., 2012).612 Cancer Cell 27, May 11, 2015 ª2015 ElsIn this issue of Cancer Cell, Welner et al.
(2015) propose an alternative explanation
for this long-standing question. They
show that leukemiccells candirectly trans-
form non-mutated HPSCs into functional
‘‘leukemic-like’’ progenitor cells.
Welner et al. (2015) used the Scl/Tal1-
tTA x TRE-BCR/ABL double transgenic
mouse model of inducible CML (upon
tetracycline removal), previously utilized
by this and other groups. To study the
interaction between mutated and non-
mutated hematopoietic cells—a novel
aspect that is also more similar to the hu-
man disease—the authors transplanted
wild-type hematopoietic cells expressing
the CD45.1 isotype together with either
SCL-tTA x BCR-ABL CD45.2 leukemic
cells or wild-type CD45.2 control cells
into lethally irradiated CD45.1 mice.
Following transplantation, mice were
administered tetracycline for 16 weeksevier Inc.to establish hematopoietic homeostasis
and then CML was induced by tetracy-
cline removal.
Taking advantage of these chimeric
mice, the authors could study the interac-
tion between mutated and non-mutated
‘‘leukemic-exposed’’ cells. Surprisingly,
non-mutated cells exposed to leukemic
cells adopted some of their features, such
as the excessive production of myeloid
cells and the deficient generation of
lymphoid cells. To understand the cause
of this bias in myeloid/lymphoid lineage
differentiation, the authors analyzed he-
matopoietic progenitors—defined as cells
expressing the antigens c-kit (at high
levels) and sca-1 but lacking expression
of lineage markers expressed in mature
hematopoietic cells (KSL)—short-term
(ST)-HSCs (CD34+ Flt3 KSL cells), and
long-term (LT)-HSCs (CD150+ CD48
KSL cells). Interestingly, leukemic-ex-
posed progenitors or ST-HSCs, but not
the leukemic-exposed HSCs, showed
increased proliferation and accumulation.
Subsequent experiments confirmed a
clear progenitor bias toward production
ofmyeloid cells at the expense of lymphoid
lineages, resembling themutated leukemic
progenitors. However, that was not
the case for HSCs, which showed in-
stead impaired self-renewal and reduced
capacity to reconstitute the hematopoi-
etic system of transplanted secondary
recipients.
To investigate the mechanisms leading
to these functional modifications, the re-
searchers performed genome-wide gene
profiling of purified control or leukemic-
exposed HSPCs. Interestingly, Gene
Set Enrichment Analysis (GSEA) showed
a BCR-ABL+ signature in leukemic-ex-
posed progenitors that closely resembled
that of mutated leukemic cells. Addi-
tionally, the transcriptome of leukemic-
exposed HSCs was consistent with
deficient self-renewal and bone marrow
engraftment.
Buthowcan leukemiccellsmakenormal
cells act alike? It was previously shown
that CML generates an inflammatory envi-
ronment (Reynaud et al., 2011; Kleppe
et al., 2015).Welner et al. (2015) confirmed
the increased production of the pro-in-
flammatory cytokines GM-CSF, IL-6, and
IL-1a in the chimeric mice. Based on the
known functions of each cytokine, the au-
thors focused their attention on IL-6, which
had been previously shown to modify
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Could this cytokine also transform the
function of the normal HSPCs? Consistent
with the different effects of the leukemic
cells on normal HSCs and progenitors,
expression of the IL-6 receptor was found
to bemuch higher in the latter. The authors
went on to perform loss-of-function exper-
iments using IL-6 blocking antibodies and
an inducible Mx1-Cre;IL-6Raflox/flox sys-
tem. Both the pharmacological blockade
and genetic deletion experiments showed
a complete yet transient phenotypic rever-
sion in leukemic-exposed hematopoietic
progenitors. Reduced IL-6 production
and rescue of the induced leukemic-
like phenotypes were also observed in
chimeric mice treated with imatinib, the
tyrosine-kinase inhibitor currently used to
treat CML patients.
To address the relevance to human dis-
ease, Welner et al. (2015) cultured adult
bone marrow CD34+ cells mixed with
bone marrow from either healthy subjects
or CML patients, obtaining similar results
as in the mouse model, i.e., increased
IL-6 content and CD34+ cell proliferation,
but decreased lymphoid production.
These phenotypes were also reverted by
IL-6 inhibition.
A recent study has shown that both the
mutated and non-mutated leukemic-
exposed hematopoietic cells produce in-
flammatory cytokines in MPN (Kleppe
et al., 2015). This study found IL-6 to bemainly secreted by the mutated cells.
Although the mutations explored in the
Welner et al. (2015) study and the Kleppe
et al. (2015) study are different, parallels
from both studies point toward a scenario
in which IL-6 secretion by mutant cells
transforms normal hematopoietic cells
into leukemic-like cells.
In summary, several alterations of
normal bone marrow cells induced by
mutated HSPCs are required for the
manifestation and progression of MPN
(Figure 1): (1) neuroglial damage in the
bone marrow and induced apoptosis of
HSC-niche forming nestin+ MSC, leading
to uncontrolled proliferation of mutated
HSCs (Arranzetal., 2014); (2)productionof
pro-inflammatory cytokines by leukemic
and normal cells (Reynaud et al., 2011;
Kleppe et al., 2015); (3) induction of some
leukemic-like features in the normal he-
matopoietic progenitors (Welner et al.,
2015); and (4) excessive proliferation of
osteoblastic precursors that become less
supportive for hematopoietic progenitors
(Krause et al., 2013; Schepers et al., 2013).
Targeting the non-mutated bone
marrow cells therefore opens up an
attractive door for the development of
new therapeutic strategies.REFERENCES
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Ependymomas have a variable prognosis. In this issue of Cancer Cell, Pajtler and colleagues identify nine
subgroups of ependymoma using DNA methylation profiles. Two subgroups, predominately pediatric, are
responsible for most of the mortality, with all others having nearly 100% overall survival after 5 years.For the past several decades, there has
been little progress in the treatment of
ependymomas. Currently, treatment islargely restricted to maximal surgical
resection and, in some cases, external
beam radiation. The tumors do not con-sistently respond to chemotherapy, and
clinical behavior is not accurately pre-
dicted by histologic grade. Currentl 27, May 11, 2015 ª2015 Elsevier Inc. 613
